News
ALGS
0.8236
+2.82%
0.0226
Weekly Report: what happened at ALGS last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ALGS last week (0408-0412)?
Weekly Report · 04/15 09:18
Weekly Report: what happened at ALGS last week (0401-0405)?
Weekly Report · 04/08 09:19
ALIGOS THERAPEUTICS INC - TOPLINE SAFETY AND EFFICACY DATA FROM THIS STUDY ARE EXPECTED IN Q4 2024
Reuters · 04/03 12:00
Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH
Healthcare Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada's CADTH. Mirum Pharmaceuticals, Inc. (MIRM) StockFSV, BSEP, ALGS, IBAT is up 1% in pre-market trading.
Seeking Alpha · 04/02 12:59
Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
Benzinga · 04/01 15:31
Weekly Report: what happened at ALGS last week (0325-0329)?
Weekly Report · 04/01 09:18
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
NASDAQ · 03/27 13:55
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
Aligos Therapeutics, Inc. Is a clinical stage biopharmaceutical company focused on developing novel therapeutics for liver and viral diseases. Aligos will present three oral presentations and one poster presentation at the Asian Pacific Association for the Study of the Liver 2024 in Kyoto, Japan. The company's ALG-055009 is a potential best-in-class small molecule for chronic hepatitis B.
Benzinga · 03/27 12:06
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Aligos Therapeutics, Inc. Will present at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver in March 2024 in Kyoto, Japan. The company is focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases.
Barchart · 03/27 07:00
Weekly Report: what happened at ALGS last week (0318-0322)?
Weekly Report · 03/25 09:19
Weekly Report: what happened at ALGS last week (0311-0315)?
Weekly Report · 03/18 09:18
12 Health Care Stocks Moving In Friday's After-Market Session
Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. Aclarion and SCWorx stock rose by 10.39% and 7.55% respectively.
Benzinga · 03/15 21:33
Maintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics’ Clinical Pipeline
TipRanks · 03/15 05:25
Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences
TipRanks · 03/14 06:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Aligos Therapeutics (ALGS)
TipRanks · 03/13 06:00
Aligos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Aligos Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 22 cents per share. Revenue fell 43.2% to $2.01 million from the same quarter last year. The mean expectation of two analysts was for a loss of 27 cents.
Reuters · 03/12 21:56
Recap: Aligos Therapeutics Q4 Earnings
Aligos Therapeutics reported its Q4 earnings on March 12. The company beat estimates by 19.0%. The company's revenue was down $1.53 million from the same period last year. Last quarter the company beat on EPS by $0.06.
Benzinga · 03/12 20:30
*Aligos Therapeutics 4Q Loss/Shr 22c >ALGS
Dow Jones · 03/12 20:05
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.